title: A comprehensive map of the mTOR signaling network.
abstract: The mammalian target of rapamycin (mTOR) is a central regulator of cell growth and proliferation. mTOR signaling is frequently dysregulated in oncogenic cells, and thus an attractive target for anticancer therapy. Using CellDesigner, a modeling support software for graphical notation, we present herein a comprehensive map of the mTOR signaling network, which includes 964 species connected by 777 reactions. The map complies with both the systems biology markup language (SBML) and graphical notation (SBGN) for computational analysis and graphical representation, respectively. As captured in the mTOR map, we review and discuss our current understanding of the mTOR signaling network and highlight the impact of mTOR feedback and crosstalk regulations on drug-based cancer therapy. This map is available on the Payao platform, a Web 2.0 based community-wide interactive process for creating more accurate and information-rich databases. Thus, this comprehensive map of the mTOR network will serve as a tool to facilitate systems-level study of up-to-date mTOR network components and signaling events toward the discovery of novel regulatory processes and therapeutic strategies for cancer.
authors.affiliation: Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Canada.
authors.forename: Etienne
authors.initials: E
authors.lastname: Caron
authors.forename: Samik
authors.initials: S
authors.lastname: Ghosh
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Matsuoka
authors.forename: Dariel
authors.initials: D
authors.lastname: Ashton-Beaucage
authors.forename: Marc
authors.initials: M
authors.lastname: Therrien
authors.forename: Sébastien
authors.initials: S
authors.lastname: Lemieux
authors.forename: Claude
authors.initials: C
authors.lastname: Perreault
authors.forename: Philippe P
authors.initials: PP
authors.lastname: Roux
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kitano
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D053263:Gene Regulatory Networks; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy; D025941:Protein Interaction Mapping; D015398:Signal Transduction; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use; D049490:Systems Biology; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus